Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 4, 1996, Pages 378-384

  Kreis, Willi ^a   Budman, Daniel R ^a   Vinciguerra, Vincent ^a   Hock, Kathleen ^a   Baer, Joann ^a   Ingram, Richard ^b   Schacter, Lee P ^c   Fields, Scott Z ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

High dose etoposide phosphate; Pharmacokinetics

Indexed keywords

ETOPOFOS; ETOPOSIDE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; ETOPOSIDE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS;

EID: 0029947578     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050498     Document Type: Article

References (22)

1. Stahelin H, Wartburg A von (1989) From podophyllotoxin glucoside to etoposide. Progr Drug Res 33: 169-266
2. Brown RA, Herzig RH, Wolff SN, Frei-Lahr D, Pineiro L, Bolwell BJ, Lowder J, Harden E, Hande K and Herzig G (1990) High dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 76: 473-479
3. Blume KG, Forman SJ (1992) High-dose etoposide (VP-16) containing preparatory regimens in allogenic and autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 19 [suppl 13]: 63-66
4. Spitzer TR, Cottler-Fox M, Torrisi J, Cahill R, Greenspan A, Lynch M and Deeg HJ (1989) Escalating doses of etoposide with cyclophosphamide and fractionated total body radiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 4: 559-565
5. Chao NJ, Stein AS, Long D, Negrin R, Amylon M, Wong R, Forman S, Blume K (1993) Busulfan/etoposide - initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 81: 319-323
6. Linker CA, Ries CA, Damon LE, Rugo H, Wolf J (1993) Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 81: 311-318
7. Etoposide phosphate (BMY-4048) (1991) Investigator Brochure on file with the Food and Drug Administration, Washington, DC
8. Budman DR, Igwemezie LN, Kaul S, Behr J, Lichtman S, Schulman P, Vinciguerra V, Allen S, Kolitz J, Hock K, O'Neill K, Schacter L, Barbhaiya R (1994) Phase I evaluation of a water soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1,3 and 5 in patients with solid tumors. J Clin Oncol 12: 1902-1909
9. Kreis W, Budman DR, Fields SZ, Hock K, Schacter L (1995) Pharmacologic evaluation of high dose etoposide phosphate with g-csf administered as a 2 hour infusion daily × 2 in patients with solid tumors. Proc AACR 36: 233
10. Gibaldi M, Perrier D (1982) Pharmacokinetics (2nd edn). Marcel Dekker, New York, pp 409-417
11. Kreis W, Rottach C, Budman DR, Chan K, Schulman P, Allen S, Weiselberg L, Vinciguerra V (1988) Pharmacokinetics and phase I evaluation of esorubicin (4'deoxydoxorubicin) by continuous infusion over forty eight hours in patients with leukemia. Cancer Res 48: 5580-5584
12. Sessa C, Zucchetti M, Cerny T, Pagani O, Cavalli F, DeFusco M, DaJong J, Gentili D, McDaniel C, Prins C, Schacter L, Winograd B, D'Incalci M (1995) Phase I and clinical pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 13: 200-209
13. Thompson DS, Greco FA, Miller AA, Srinivas N, Igwenezue K, Hainsworth J, Schacter L, Kaul S, Barbhaiya R, Garrow C (1995) A phase I study of etoposide phosphate administered as a daily 30 minute infusion for 5 days. Clin Pharmacol Ther 57: 499-507
14. Beckman G, Beckman L (1984) Human alkaline phosphatase isozymes, genetic variations and their relationship to natural selection. In: Stigbrand T, Fishermen WH (eds.) Human Alkaline Phosphatases, AR Liss, New York, pp 15-23
15. Horning SJ, Negrin RS, Chao NJ, Long GD, Hoppe RT, Blume KG (1994) Fractionated total body irradiation, etoposide and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12: 2552-2558
16. Kohl P, Köppler H, Schmidt L, Fritsch HW, Holz J, Pfluger KH, Jungclas H (1992) Pharmacokinetics of high dose etoposide after short term infusion. Cancer Chemother Pharmacol 29 : 316-320
17. Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN (1984) Pharmacokinetics of high dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 44: 379-382
18. Newman EM, Doroshow JH, Forman SJ, Blume KG (1988) Pharmacokinetics of high dose etoposide. Clin Pharmacol Ther 43: 561-564
19. Schwinghammer TL, Fleming RA, Rosenfeld CS, Przepiorka D, Shadduck R, Bloom E, Stewart C (1993) Disposition of total and unbound etoposide following high dose therapy. Cancer Chemother Pharmacol 32: 273-278
20. Relling M, McLeod HL, Bowman LC, Santana V (1994) Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 56: 503-511
21. Mross K, Bewermeier P, Krüger W, Stockschlader M, Zander A, Hossfeld DK (1994) Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. J Clin Oncol 12: 1468-1474
22. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1996) Quantitative comparison of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 50: 219-245